Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics
Publication Date Oct 2014
Publisher CurrentPartnering
Product Type Report
Pages 652
Single User License help $ 1995.00
Site User License help $ 5995.00
Corporate User License help $ 9995.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.
 
This new 1st edition, includes:
 
Trends in joint venture deals
Joint venture agreement structure
Joint venture contract documents
Top joint venture deals by value
Most active joint venture dealmakers
Comprehensive directory of joint venture deals since 2009
 
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
 
The report provides details of joint venture agreements from 2009 to end of August 2014.
 
The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                               
This report contains a comprehensive listing of all joint venture deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
 Report scope        
Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading biopharma companies worldwide.
 
Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics includes:
                                                       
Trends in joint venture dealmaking in the biopharma industry since 2009
Analysis of joint venture deal structure
Case studies of real-life joint venture deals
Access to over 450 joint venture deal records
Detailed access to actual joint venture contract documents
The leading joint venture deals by value since 2009
Most active joint venture dealmakers since 2009
The leading joint venture partnering resources
 
 In Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics, the available contracts are listed by:
 
Company A-Z
Headline value
Stage of development at signing
Therapeutic area
Technology area
 
Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.
 
The Global Joint Venture Partnerships report provides comprehensive access to records for over 450 joint venture deals. Analyzing actual contract agreements allows assessment of the following:
                                
What are the precise joint venture rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law

Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
In-depth understanding of joint venture deal trends since 2009
Analysis of the structure of joint venture agreements with numerous real life case studies
Comprehensive access to over 450 joint venture deals entered into by the world’s biopharma companies, together with contract documents if available
Detailed access to actual joint venture contracts entered into by the leading fifty big pharma and big biotech companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Identify leading joint venture deals by value since 2009
Identify the most active joint venture dealmakers since 2009
Full listing of joint venture deals by company A-Z, headline value, phase of development, deal type, therapy and technology focus

TABLE OF CONTENTS

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in joint venture partnerships
 
2.1. Introduction
2.2. Definition of joint venture deals
2.3. Success factors for joint venture partnerships
2.4. When joint venture partnerships can be useful
2.5. Attributes of joint venture partnerships
2.6. Aligning partners to make the joint venture work
2.7. Trends in joint venture partnerships since 2009
2.8. The future of joint venture partnerships
 
Chapter 3 – Overview of joint venture deal structure
 
3.1. Introduction
3.2. Joint venture agreement structure
3.3. Example joint venture agreements
3.3.1. Case study 1: Agila Specialties - Pfenex – April 2013
3.3.1.b. Case study 2: Dance Biopharm – Harmony Asset – October 2013
 
Chapter 4 – Leading joint venture deals
 
4.1. Introduction
4.2. Top joint venture deals by value
4.3. Most active joint venture dealmakers
4.4. Bigpharma joint venture deal activity
 
Chapter 5 – Bigpharma joint venture deals
 
5.1. Introduction
5.2. How to use joint venture deals
5.3. Company joint venture agreement listings
Abbott
Abbvie
Actavis
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Roche Diagnostics
Sanofi
Servier
Shionogi
Shire
Sun Pharmaceutical
Takeda
Teva
UCB
Valeant
 
Chapter 6 – Bigbiotech joint venture deals
 
6.1. Introduction
6.2. How to use joint venture deals
6.3. Company joint ventuure agreement listings
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
AMAG Pharmaceuticals
Amgen
Anika Therapeutics
Array Biopharma
Bavarian Nordic
Biocon
Biogen Idec
BioMarin Pharmaceuticals
Cangene
Celgene
CSL
Cubist
Dendreon
Elan
Emergent BioSolutions
Enzo Biochem
Galapagos
Genmab
Gilead Sciences
Grifols
Ipsen
Isis Pharmaceuticals
LFB Group
Medivation
Morphosys
Nektar Therapeutics
Novo Nordisk
NPS Pharmaceuticals
Onyx Pharmaceuticals
Optimer
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
Roche
SciClone Pharmaceuticals
Seattle Genetics
Shire
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
UCB
United Therapeutics
Vertex Pharmaceuticals
ViroPharma
Zeltia
 
Chapter 7 – Joint venture contract directory 2009-2014
 
7.1. Introduction
7.2. Company A-Z
7.3. By therapy area
7.4. By stage of development at signing
7.5. By technology area
 
Appendix
 
Appendix 1 – Joint venture dealmaking – by company A-Z
Appendix 2 – Joint venture dealmaking – by stage of development
Appendix 3 - Joint venture dealmaking – by therapeutic target
Appendix 4 - Joint venture dealmaking – by technology type
Appendix 5 – Joint venture references
Appendix 6 – Resources
Appendix 7 – Deal type definitions
 
About Wildwood Ventures
Current Partnering
Current Agreements
Order Form – Upgrades to subscription access products
Recent report titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES
 
Figure 1: Definition of joint venture
Figure 2: Situations where joint venture partnerships can prove useful
Figure 3: Key components of a joint venture partnership
Figure 4: Issues in implementing joint venture partnership agreements
Figure 5: Trends in joint venture deal announcements, 2009-2014
Figure 6: Joint venture deals signed at each phase of development, 2009-2014
Figure 7: Joint venture shareholder agreements – what should a contract include?
Figure 8: Components of the joint venture deal structure
Figure 9: Top joint venture deals by value since 2009
Figure 10: Most active joint venture dealmakers 2009-2014
Figure 11: Bigpharma – top 50 – Joint venture deals 2009 to 2014
Figure 12: Bigpharma joint venture deal frequency - 2009 to 2014
Figure 13: Online partnering resources
Figure 14: Deal type definitions

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
Abdominal Obesity-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abdominal Obesity-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establ ...Read More
$1250.00
Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abortion-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abscess-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abscess-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the un ...Read More
$1250.00
Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and m ...Read More
$2000.00
Absence Seizure-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase II ...Read More
$2000.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z